Recombinant Human PLA2G7 (C-6His)

Description

EnkiLife provides the Recombinant Human PLA2G7 (C-6His) protein,aslo know as Platelet-Activating Factor Acetylhydrolase,PAF Acetylhydrolase,1-Alkyl-2-Acetylglycerophosphocholine Esterase,2-Acetyl-1-Alkylglycerophosphocholine Esterase,Group-VIIA Phospholipase A2,gVIIA-PLA2,LDL-Associated Phospholipase A2,LDL-PLA(2),PAF 2-Acylhydrolase,PLA2G7,PAFAH, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human Platelet-Activating Factor Acetylhydrolase is produced by our Mammalian expression system and the target gene encoding Phe22-Asn441 is expressed with a 6His tag at the C-terminus.Accession:AAH38452.1. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:48.8 KDa. Background:Platelet-Activating Factor Acetylhydrolase (PAFAH) is a secreted enzyme which belongs to the AB hydrolase superfamily and Lipase family and catalyzes the degradation of platelet-activating factor to biologically inactive products. PAFAH is produced by inflammatory cells and hydrolyzes oxidised phospholipids in LDL. PAFAH has been implicated in the development of atherosclerosis and has also been identified as a marker for cardiac disease. PAFAH might have a major physiologic effect in the presence of inflammatory bodily responses. PAFAH alters the action of PAF by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. PAFAH has specificity for substrates with a short residue at the sn-2 position.